Dr. Reddy’s Laboratories, Lilly sign deal for Covid-19 drug baricitinib

Dr. Reddy’s Laboratories, Lilly sign deal for Covid-19 drug baricitinib

Dr. Reddy’s Laboratories said that it has forged a royalty-free, non-exclusive voluntary licensing agreement with US pharma giant Eli Lilly and Company (Lilly) for the manufacturing and commercialization of Covid-19 drug baricitinib in India. Baricitinib in combination with remdesivir had been given restricted emergency use approval by the Indian Central Drugs Standard Control Organization (CDSCO). […]

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to the latter’s baricitinib in India. The Indian pharma company Sun Pharma will manufacture and distribute baricitinib in India. Baricitinib has been granted restricted emergency use by India’s Central Drugs Standard […]

Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India

Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India

Lupin Limited said that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling the latter’s Baricitinib in India. Baricitinib is an oral JAK1/JAK2 inhibitor for which India’s Central Drugs Standard Control Organization (CDSCO) had been given restricted emergency use in combination with Remdesivir for […]

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients

Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19. The Indian pharma company has been given the nod for Lilly’s oral JAK1/JAK2 inhibitor in 1mg, 2mg and 4mg strengths in combination with Remdesivir. Natco Pharma said that it will be seeking a […]

Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]

Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, Covid-19 infected individuals. Recently, bamlanivimab was granted emergency use authorization (EUA) from the US Food and Drug Administration for the treatment of Covid-19 patients having mild to moderate […]

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]

Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt

Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt

Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, an investigational neutralizing antibody for the treatment of Covid-19. LY-CoV555 is the first antibody candidate to come out from Lilly’s collaboration with AbCellera Biologics, which was announced in March this […]